Rifampicin-Loaded Mesoporous Silica Nanoparticles for the Treatment of Intracellular Infections

Subramaniam,; Thomas, Nicky; Gustafsson, Finn; Jambhrunkar,; Kidd, Stephen P.; Prestidge, Clive A.

doi:10.3390/antibiotics8020039

Cited by 48 publications

(51 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, some researchers are trying to improve the activity of antibacterial drugs against SCV phenotypes of S. aureus by using nanoparticles. Subramaniam et al (2019), used the mesoporous silica nanoparticles (MSNP) loaded with the rifampicin as a nanocarrier system in the treatment of intracellular infection caused by SCVs of S. aureus. In this study, the MSNP with two sizes 40 nm and 100 nm loaded with the rifampicin showed more bactericidal activity than rifampicin alone by enhancing the intracellular rifampicin uptake by RAW 264.7 macrophage infected with SCVs of S. aureus.…”

Section: Enhanced Intracellular Deliverymentioning

confidence: 99%

Nanoparticles for treatment of bovine Staphylococcus aureus mastitis

2020

View full text Add to dashboard Cite

Staphylococcus aureus (S. aureus) is one of the most important zoonotic bacterial pathogens, infecting human beings and a wide range of animals, in particular, dairy cattle. Globally. S. aureus causing bovine mastitis is one of the biggest problems and an economic burden facing the dairy industry with a strong negative impact on animal welfare, productivity, and food safety. Furthermore, its smart pathogenesis, including facultative intracellular parasitism, increasingly serious antimicrobial resistance, and biofilm formation, make it challenging to be treated by conventional therapy. Therefore, the development of nanoparticles, especially liposomes, polymeric nanoparticles, solid lipid nanoparticles, nanogels, and inorganic nanoparticles, are gaining traction and excellent tools for overcoming the therapeutic difficulty accompanied by S. aureus mastitis. Therefore, in this review, the current progress and challenges of nanoparticles in enhancing the S. aureus mastitis therapy are focused stepwise. Firstly, the S. aureus treatment difficulties by the antimicrobial drugs are analyzed. Secondly, the advantages of nanoparticles in the treatment of S. aureus mastitis, including improving the penetration and accumulation of their payload drugs intracellular, decreasing the antimicrobial resistance, and preventing the biofilm formation, are also summarized. Thirdly, the progression of different types from the nanoparticles for controlling the S. aureus mastitis are provided. Finally, the difficulties that need to be solved, and future prospects of nanoparticles for S. aureus mastitis treatment are highlighted. This review will provide the readers with enough information about the challenges of the nanosystem to help them to design and fabricate more efficient nanoformulations against S. aureus infections. ARTICLE HISTORY ). So, these new nanocarriers provide a new strategy to combat S. aureus mastitis problems. In order to provide an overview of the emerging nanocarriers in the bovine mastitis management and help the researcher to understand how they can discover a new trend to combat S. aureus mastitis by shifting their attention toward the world of nanocarriers. We searched PubMed, Scopus, and Web of Science for all the studies published over the last 20 years using the keywords "S. aureus mastitis" or "virulence factors of S. aureus" and "antimicrobial resistance" or "nanoparticles and nanogel". About 3000 records and 550 of closely related papers were screened for suitable studies. We summarized the features and treatment difficulty of S. aureus mastitis, the advantages, and prospects of nanoparticles and nanogels according to the related publications.

show abstract

Section: Enhanced Intracellular Deliverymentioning

confidence: 99%

Nanoparticles for treatment of bovine Staphylococcus aureus mastitis

2020

View full text Add to dashboard Cite

show abstract

“…In another interesting set of contributions, Subramaniam et al and Joyce et al evaluated the behavior between MSNs with different particle sizes 41 and surface functionalization 42 to be tested on S. aureus intracellular infections. In these contributions the authors employed Hiroshima mesoporous materials (HMM) with sizes in the range of 40–100 nm and rifampicin as antibiotic cargo.…”

Section: Delivery Of Antibiotic Compoundsmentioning

confidence: 99%

Recent Advances Toward the Use of Mesoporous Silica Nanoparticles for the Treatment of Bacterial Infections

Castillo

2021

IJN

View full text Add to dashboard Cite

It is a fact that the use of antibiotics is inducing a growing resistance on bacteria. This situation is not only the consequence of a drugs’ misuse, but a direct consequence of a widespread and continuous use. Current studies suggest that this effect could be reversed by using abandoned antibiotics to which bacteria have lost their resistance, but this is only a temporary solution that in near future would lead to new resistance problems. Fortunately, current nanotechnology offers a new life for old and new antibiotics, which could have significantly different pharmacokinetics when properly delivered; enabling new routes able to bypass acquired resistances. In this contribution, we will focus on the use of porous silica nanoparticles as functional carriers for the delivery of antibiotics and biocides in combination with additional features like membrane sensitizing and heavy metal-driven metabolic-disrupting therapies as two of the most interesting combination therapies.

show abstract

“…Considering the abovementioned advantages, authors have reported the use of MSNs containing peptides with antibacterial properties, aiming to prevent their enzymatic degradation potentiating their antimicrobial activity (110). It can also guarantee the same effect for loading antimicrobial proteins (115).…”

Section: Bacterial Infectionsmentioning

confidence: 99%

Highlights in Mesoporous Silica Nanoparticles as a Multifunctional Controlled Drug Delivery Nanoplatform for Infectious Diseases Treatment

et al. 2020

View full text Add to dashboard Cite

Infectious diseases are a major global concern being responsible for high morbidity and mortality mainly due to the development and enhancement of multidrug-resistant microorganisms exposing the fragility of medicines and vaccines commonly used to these treatments. Taking into account the scarcity of effective formulation to treat infectious diseases, nanotechnology offers a vast possibility of groundbreaking platforms to design new treatment through smart nanostructures for drug delivery purposes. Among the available nanosystems, mesoporous silica nanoparticles (MSNs) stand out due their multifunctionality, biocompatibility and tunable properties make them emerging and actual nanocarriers for specific and controlled drug release. Considering the high demand for diseases prevention and treatment, this review exploits the MSNs fabrication and their behavior in biological media besides highlighting the most of strategies to explore the wide MSNs functionality as engineered, smart and effective controlled drug release nanovehicles for infectious diseases treatment.

show abstract

Rifampicin-Loaded Mesoporous Silica Nanoparticles for the Treatment of Intracellular Infections

Cited by 48 publications

References 47 publications

Nanoparticles for treatment of bovine Staphylococcus aureus mastitis

Nanoparticles for treatment of bovine Staphylococcus aureus mastitis

Recent Advances Toward the Use of Mesoporous Silica Nanoparticles for the Treatment of Bacterial Infections

Highlights in Mesoporous Silica Nanoparticles as a Multifunctional Controlled Drug Delivery Nanoplatform for Infectious Diseases Treatment

Contact Info

Product

Resources

About